46th week of 2021 patent applcation highlights part 27 |
Patent application number | Title | Published |
20210355440 | ENGINEERED RED BLOOD CELLS HAVING RARE ANTIGEN PHENOTYPES - Provided herein are engineered red blood cells expressing rare blood antigen group profiles, and methods of making use the same, are described. Also provided are recombinant reagent red blood cells that express or lack the expression of at least one protein (e.g., a blood group antigen) on its surface and uses thereof. | 2021-11-18 |
20210355441 | GENERATION OF HOXA-EXPRESSING HEMOGENIC ENDOTHELIUM WITH ENHANCED T CELL POTENTIAL FROM HPSCS - The present invention provides methods of creating a population of hemogenic endothelial cells with arterial specification and enhanced T cell potential. The methods involve inducing the expression of a SOX17 transgene in human pluripotent stem cells starting at day 2 of differentiation. Stem cells that express the SOX17 transgene are also provided. | 2021-11-18 |
20210355442 | GAMMA DELTA T CELLS AND USES THEREOF - Provided are methods of expanding and isolating γδ T cells from human peripheral blood mononuclear cells (PBMCs). Also provided are isolated γδ T cells, CAR-γδ T cells, and methods of using the same. | 2021-11-18 |
20210355443 | METHODS FOR PRODUCTION OF TISSUE RESIDENT MEMORY-LIKE T CELLS AND USE THEREOF - Provided herein are methods for the production of tissue resident memory-like T cells by the combination of hypoxia and TGFβ. Further provided herein are methods of using the tissue resident memory T cells as adoptive cell therapy. | 2021-11-18 |
20210355444 | METHOD FOR PRODUCING ERYTHROID CELLS AND/OR ERYTHROCYTES - The present disclosure provides a method for producing erythroid cells and/or erythrocytes comprising culturing hematopoietic stem cells (HSCs) or erythroid cells with a population of immortalized mesenchymal stem cells (MSCs) or conditioned medium obtained from the immortalized MSCs, wherein the immortalized MSCs are genetically engineered with a survival gene. Also provided is a method of making a blood product for use in transfusions and a method for increasing hemoglobin synthesis. | 2021-11-18 |
20210355445 | KIT CONTAINING MEDIUM FOR CULTURING NATURAL KILLER CELLS AND METHOD OF EFFECTIVELY CULTURING NATURAL KILLER CELLS USING THE SAME - Disclosed is a method of culturing natural killer cells (NK cells) applied to immunotherapy. More specifically, disclosed are a kit containing a medium for culturing NK cells (NKCM kit) that can efficiently amplify and activate NK cells effective for the treatment of malignant tumors by culturing lymphocytes derived from human peripheral blood, and a method of culturing natural killer cells using the kit. The method for amplifying NK cells of the present invention includes stimulating NK cells with lymphocytes separated from peripheral blood, culturing the NK cells in a medium containing IL-2, IL-12, IL-15, IL-17, IL-18, and IL-21, and isolating the NK cells. Provided is a pharmaceutical composition for cell therapy containing NK cells produced by the method of amplifying NK cells. The pharmaceutical composition for cell therapy is expected to be widely used to treat infections and/or cancer. | 2021-11-18 |
20210355446 | ARTIFICIAL HLA-POSITIVE FEEDER CELL LINES FOR NK CELLS AND USES THEREOF - The present invention relates to the field of immunology, molecular biology and therapeutics. In particular, the invention relates to novel artificial feeder cells for activation and expansion of natural killer (NK) cells. The artificial feeder cell expresses endogenous ligands (HLA C1, C2, 5 and Bw4 type) for killer cell immunoglobulin-like receptors (KIRs), non-KIR binding Bw6 ligand, endogenous HLA-E-ligand for inhibitory NKG2A receptor, and comprises at least one stimulatory cytokine either membrane bound or secreted or at least one co-stimulatory ligand where those ligands and cytokines each specifically bind to a cognate receptor on a NK cell of interest, thereby mediating expansion of the NK cell. The invention can be used as an “off the 10 shelf” artificial feeder cell that can be readily designed to expand a NK cell or a NK subset of interest and also specifically expand NK cells modified with a chimeric antigen receptor (CAR). By genetically introducing or knockdown of candidate genes, the artificial feeder cell of the invention can be used to identify the stimulatory, co-stimulatory, and any other factors that mediate growth, expansion and cytotoxicity of a NK cell. Thus, the present invention provides 15 powerful tools for development of novel therapeutics where activation and expansion of the NK cell and of the CAR-NK cell can provide a benefit. | 2021-11-18 |
20210355447 | Multipotential Expanded Mesenchymal Precursor Cell Progeny (MEMP) and Uses Thereof - The invention relates to multipotential expanded mesenchymal precursor progeny (MEMP's), characterised by the early developmental markers STRO-1 | 2021-11-18 |
20210355448 | METHODS OF ISLET CELL CULTURE - Provided herein are, inter alia, methods, compositions, and kits for culturing and improving the quality of islet cells. Included are compositions and kits for the ex vivo culture of islets or islet cells as well as methods of making and using the same. Isolated and cultured islets and islet cells are also provided. | 2021-11-18 |
20210355449 | GENETICALLY MODIFIED STEM CELLS - Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12. | 2021-11-18 |
20210355450 | CERVICAL CANCER ORGANOIDS - The present invention relates to a method for the production of a cervix epithelial cell organoid culture. By means of this method, an organoid culture of cervix epithelial cells, and a biobank comprising a plurality of different organoid cultures thereof may be generated. Further, a culture medium suitable for the long-term culture of epithelial stem cells is provided. Furthermore, the use of the organoid culture in the biobank for medical applications, e.g. in the field of diagnostics and therapy and in the fields of drug screening and immunotherapy is described. | 2021-11-18 |
20210355451 | VIABLE BIOENGINEERED SKIN CONSTRUCTS - The present disclosure is directed to viable bioengineered skin constructs. | 2021-11-18 |
20210355452 | PURIFICATION METHOD FOR VACCINE VIRUS USING AFFINITY CHROMATOGRAPHY - The present disclosure relates to separation and purification methods for a vaccine virus using affinity chromatography, and more particularly, to a purification method for a virus capable of obtaining a vaccine virus with a high purity and a high yield using affinity chromatography containing a vaccine virus-affinity resin. | 2021-11-18 |
20210355453 | ADENOVIRUSES AND METHODS FOR USING ADENOVIRUSES - This invention relates to methods and materials for nucleic acid delivery, vaccination, and/or treating cancer. More specifically, methods and materials for nucleic acid delivery, vaccination, and/or treating cancer using one or more recombinant adenoviruses (Ads) as an oncolytic agent are provided. | 2021-11-18 |
20210355454 | SYSTEMS AND METHODS FOR PRODUCING GENE THERAPY FORMULATIONS - The present disclosure describes methods and systems for use in the production of adeno-associated virus (AAV) particles and AAV formulations, including recombinant adeno-associated virus (rAAV) particles and formulations. In certain embodiments, the present disclosure presents methods and systems for clarifying, purifying, formulating, filtering and processing AAV particles and AAV formulations. The present disclosure also describes compositions, methods and processes for the design, preparation, manufacture, use and/or formulation of AAV particles comprising modulatory polynucleotides, e.g., polynucleotides encoding small interfering RNA (siRNA) molecules which target the Huntingtin (HTT) gene (e.g., the wild-type or the mutated CAG-expanded HTT gene). Methods for using formulated AAV particles comprising modulatory polynucleotides to inhibit the HTT gene expression in a subject with a neurodegenerative disease (e.g., Huntington's Disease (HD)) are also disclosed. | 2021-11-18 |
20210355455 | MODIFIED GENE SEQUENCES ENCODING CHOLINE OXIDASE AND A METHOD FOR PREPARING BETAINE USNG THE SAME - The present invention provides at least two modified gene sequences, Sequence 1 comprising of nucleotide sequence of SEQ. ID no.1, and Sequence 2 comprising of nucleotide sequence of SEQ. ID no.2, encoding the enzyme choline oxidase wherein the gene sequences have been obtained by modifying the codA gene (Accession no. X84895) encoding choline oxidase from | 2021-11-18 |
20210355456 | RECOMBINANT VECTOR AND METHOD FOR PRODUCING RECONSTITUTED CYTOCHROME P450 OXYGENASE-REDUCTASE FUSION PROTEIN USING THE SAME - A recombinant vector according to an embodiment of the present invention may be used for producing a reconstituted cytochrome P450 oxygenase-reductase fusion protein. Oxygenase and reductase may be independently expressed in a host cell into which the recombinant vector is introduced, and then may be fused with a split intein so that it is possible to increase the heme content contained in the active site of the oxygenase and improve enzyme activity and stability. | 2021-11-18 |
20210355457 | RECOMBINANT PICHIA PASTORIS, CONSTRUCTION METHOD THEREOF, AND USE THEREOF IN EFFICIENT PREPARATION OF 15 ALPHA-D-ETHYLGONENDIONE - The present disclosure provides recombinant | 2021-11-18 |
20210355458 | UDP-DEPENDENT GLYCOSYLTRANSFERASE FOR HIGH EFFICIENCY PRODUCTION OF REBAUDIOSIDES - Provided herein are compositions and methods for improved production of steviol glycosides in a host cell. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleotide sequence encoding a | 2021-11-18 |
20210355459 | Phi29 DNA polymerase mutant with improved thermal stability and use thereof in sequencing - Provided are a Phi29 DNA polymerase mutant with improved thermal stability and an use thereof in sequencing. The phi29 DNA polymerase mutant is represented by A) or B) below: the DNA polymerase mutant represented by the A) is a protein having DNA polymerase activity that is obtained by modifying at least one amino acid residue(s) in the following six sites in a phi29 DNA polymerase amino acid sequence: the 97-th, 123-th, 217-th, 224-th, 515-th, and 474-th sites; the DNA polymerase mutant represented by the B) is a protein having DNA polymerase activity that is derived from the A) by adding a tag sequence to a terminal of the amino acid sequence of the protein represented by the A). | 2021-11-18 |
20210355460 | THERMOSTABLE TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE - Disclosed herein include recombinant terminal deoxynucleotidyl transferases (TdTs). In some embodiments, the recombinant TdT comprises an amino acid sequence that is at least 80% identical to a bovine TdT, wherein the recombinant TdT comprises one or more amino acid substitution mutations at one or more positions functionally equivalent to Glu191, Lys193, Glu194, Asp242, Lys287, Phe296, Met299, Thr342, and His421 in the bovine TdT. | 2021-11-18 |
20210355461 | NOVEL PSICOSE-6-PHOSPHATE PHOSPHATASE, COMPOSITION FOR PRODUCING PSICOSE INCLUDING SAID ENZYME, METHOD FOR PRODUCING PSICOSE USING SAID ENZYME - The present application relates to a psicose-6-phosphate phosphatase comprising motif A and motif B, a composition for producing D-psicose comprising the enzyme, and a method for producing D-psicose using the enzyme. | 2021-11-18 |
20210355462 | THERAPEUTIC NUCLEASE-ALBUMIN FUSIONS AND METHODS - The invention provides for hybrid nuclease-albumin molecules with increased pharmacokinetic properties. The hybrid nuclease-albumin molecules of the invention have one or more nuclease domains (e.g., an RNase and/or DNase domain) operably coupled to an albumin, or a variant or fragment thereof. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response. | 2021-11-18 |
20210355463 | MESSENGER RNA ENCODING CAS9 FOR USE IN GENOME-EDITING SYSTEMS - The present disclosure provides optimized mRNAs encoding a site-directed endonuclease for use in a CRISPR/Cas system. Also provided herein are delivery systems for use of the CRISPR/Cas system in methods of in vivo and ex vivo genome editing. | 2021-11-18 |
20210355464 | METHOD FOR TREATING MUSCULAR DYSTROPHY BY TARGETING UTROPHIN GENE - Polynucleotides comprising the following base sequences:
| 2021-11-18 |
20210355465 | Engineered CRISPR-Cas9 Nucleases - Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenomic engineering, genome targeting, and genome editing. | 2021-11-18 |
20210355466 | OPTIMIZED PROTEIN LINKERS AND METHODS OF USE - The invention relates to peptide linkers and fusion proteins comprising linkers designed for optimizing the activity of the proteins comprised therein, and methods for using the same. The invention further relates to newly designed Cas12a-based cytosine base editors. | 2021-11-18 |
20210355467 | Cascade/dCas3 Complementation Assays for In Vivo Detection of Nucleic Acid-Guided Nuclease Edited Cells - The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions. | 2021-11-18 |
20210355468 | COMPOSITIONS AND METHODS FOR TREATING LEWY BODY DEMENTIA - Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB. The therapeutic payloads can be effective in the treatment of Lewy body dementia. Methods of treating Lewy body dementia and pharmaceutical compositions are also disclosed. | 2021-11-18 |
20210355469 | ALPHA-AMYLASES WITH MUTATIONS THAT IMPROVE STABILITY IN THE PRESENCE OF CHELANTS - Disclosed are variant α-amylases having mutations that improve enzyme stability in the presence of chelants, methods of designing such variants, and methods of use, of the resulting variants. The variant α-amylases are particularly useful, for use in cleaning and desizing composition that include significant amounts of chelants. | 2021-11-18 |
20210355470 | ALPHA-AMYLASE VARIANTS - The present invention relates to variants of a parent alpha-amylase. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | 2021-11-18 |
20210355471 | LACTASE ENZYMES WITH IMPROVED PROPERTIES - The present invention relates to new improved peptide or dimeric peptides exhibiting betagalactosidase enzyme activity as well as improved methods for reducing the lactose content in compositions, such as dairy products. | 2021-11-18 |
20210355472 | METHODS OF RECOMBINANTLY PRODUCING NEUTRAL PROTEASE ORIGINATING FROM PAENIBACILLUS POLYMXA - The present disclosure provides the sequence of a | 2021-11-18 |
20210355473 | CHIMERIC CLOTTING FACTORS - Chimeric clotting factors which localize the therapeutic to sites of coagulation (e.g., by being targeted to platelets or being activatable at sites of coagulation), have reduced clearance rates, have improved manufacturability, have reduced thrombogenicity, have enhanced activity, or have more than one of these characteristics are described as are methods for making chimeric clotting factors and methods for improving hemostasis using these clotting factors. | 2021-11-18 |
20210355474 | MODIFIED MEMBRANE TYPE SERINE PROTEASE 1 (MTSP-1) POLYPEPTIDES AND METHODS OF USE - Provided are MTSP-1 polypeptides modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to inhibit its activity and thereby inhibit complement activation. The modified MTSP-1 polypeptides that inhibit complement activation can be used for treatment of diseases and conditions in which complement activation plays a role. Such diseases and conditions include inflammatory diseases and diseases with an inflammatory component. Exemplary of these disorders are ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, ophthalmic disorders, such as diabetic retinopathies and macular degeneration, including age-related macular degeneration (AMD), and transplanted organ rejection, such as renal delayed graft function (DGF). | 2021-11-18 |
20210355475 | OPTIMIZED BASE EDITORS ENABLE EFFICIENT EDITING IN CELLS, ORGANOIDS AND MICE - The present disclosure provides nucleobase editors that include a cytidine deaminase domain, a codon-optimized nuclease-defective Cas9 domain, and at least one nuclear-localization sequence. The nucleobase editors disclosed herein improve the efficiency by which single-nucleotide variants can be created compared to conventional BE3 nucleobase editors. | 2021-11-18 |
20210355476 | BIFUNCTION CHEMICAL EPIGENENTIC MODIFIERS AND METHODS OF USE - The present disclosure relates to bifunctional chemical epigenetic modifiers, and methods of making, kits and using the bifunctional chemical epigenetic modifiers. The bifunctional chemical epigenetic modifiers can include a FK506 molecule or derivative thereof, a linker and a bifunctional ligand. The bifunctional ligand can be a histone deacetylase inhibitor. | 2021-11-18 |
20210355477 | MUTANT OF LYCOPENE EPSILON CYCLASE (LCYE) GENE CRUCIAL IN WHEAT CAROTENOID SYNTHESIS PATHWAY AND USE THEREOF - The present disclosure discloses a mutant of a lycopene epsilon cyclase (Lcye) gene crucial in a wheat carotenoid synthesis pathway and use thereof. The present disclosure provides the following proteins: (1) a protein obtained by substituting serine at position 253 of an Lcye-D1 protein with phenylalanine; (2) a derived protein that is obtained by subjecting the protein in (1) to substitution and/or deletion and/or addition of one or more amino acid residues and has the same ability as the protein in (1); (3) a protein that has a homology of more than 99%, more than 95%, more than 90%, more than 85%, or more than 80% with the amino acid sequence defined in any one of (1) and (2) and has the same function as the amino acid sequence; and (4) a fusion protein obtained by attaching a tag to N-terminus and/or C-terminus of the protein in any one of (1) to (3). The present disclosure not only verifies the function of an Lcye gene, but also provides a theoretical basis and a germplasm resource for improving the color character of flour and products thereof | 2021-11-18 |
20210355478 | METHOD FOR PREPARING ELECTROCOMPETENT YEAST CELLS, AND METHOD FOR USING SAID CELLS - The present invention relates to improved yeast transformation of yeast cells and yeast cell libraries transformed thereby. More specifically, the present invention relates to the transformation of yeast by electroporation. | 2021-11-18 |
20210355479 | PARAMETERS FOR CONCENTRATION AND WASHING OF PARTICLES WITH ACOUSTICS - Multi-stage acoustophoretic devices for continuously separating a second fluid or a particulate from a host fluid are disclosed. Methods of operating the multi-stage acoustophoretic devices are also disclosed. The systems may include multiple acoustophoretic devices fluidly connected to one another in series, each acoustophoretic device comprising a flow chamber, an ultrasonic transducer capable of creating a multi-dimensional acoustic standing wave, and a reflector. The systems can further include pumps and flowmeters. | 2021-11-18 |
20210355480 | Method For Creating Reference Cell Lines With Simultaneous Genetic Variants And Accurate Quantification Of Alelle Frequency - A method to simultaneously create multiple SNV, INDEL or fusion sequences harbored in a single cell line is provided. The method uses the CRISPR/Cas9 gene editing system to generate large sequence knock-in cell lines in an AAVS1 locus, or other safe harbor sites. Also provided is a method that allows specifically engineered quantitative marker sequences to accurately reflect copy numbers of inserted SNV, INDEL and fusion sequences. These methods allow accurate measurement of ratio or allele frequencies of genetic variants in a cell. | 2021-11-18 |
20210355481 | AAV CAPSID PROTEINS FOR NUCLEIC ACID TRANSFER - Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided. | 2021-11-18 |
20210355482 | TARGET IRRELEVANT GUIDE RNA FOR CRISPR - The present invention relates to a method of obtaining an enriched population of a target polynucleotide using a synthetic single guide RNA (sgRNA) for an sgRNA-guided nucleic acid-binding protein, as well as to a method of obtaining a pool of target-irrelevant synthetic single guide RNAs (sgRNAs) for a sgRNA-guided nucleic acid-binding protein. Also provided is a target polynucleotide and sgRNAs obtainable by the methods of the invention. Further envisaged is a kit comprising a pool of sgRNAs obtainable by the method of the invention, and the use of a pool of sgRNAs obtainable by the methods of the invention. | 2021-11-18 |
20210355483 | METHODS AND KITS USING NUCLEIC ACID ENCODING AND/OR LABEL - Methods and Kits for analyzing macromolecules, including peptides, polypeptides, and proteins, employing nucleic acid encoding are disclosed. The sample analysis kits employ nucleic acid encoding and/or nucleic acid recording of a molecular interaction and/or reaction, such as recognition events (e.g., between an antigen and an antibody, between a modified terminal amino acid residue, or between a small molecule or peptide therapeutic and a target, etc.). Assays that do not require the cyclic transfer of information between a coding tag and a recording tag are also disclosed, including single cycle assays. | 2021-11-18 |
20210355484 | PRIMERS FOR IMMUNE REPERTOIRE PROFILING - Disclosed herein include systems, methods, compositions, and kits for immune repertoire profiling. There are provided, in some embodiments, primer panels enabling the determination of the nucleotide sequence of the complete variable region of nucleic acids encoding mouse B cell receptor (BCR) and T cell receptor (TCR) polypeptides. In some embodiments, the method comprises single cell transcriptomic analysis. | 2021-11-18 |
20210355485 | METHODS FOR TARGETED NUCLEIC ACID LIBRARY FORMATION - The present disclosure provides targeted hybridization and/or proximity ligation of a probe for amplification and analysis of target sequences. The hybridization of the probe to the target sequences can be direct or through indirect association. | 2021-11-18 |
20210355486 | CATALYTIC BIOMOLECULE ACTIVITY RECORDING INTO DNA SEQUENCE - The present invention relates to catalytic biomolecule characterization and microfluidics. It is used for identification of nucleic acids encoding active catalytic molecules in the plurality of nucleic acids and for gathering information about catalytic biomolecule activity. It can also be used for exploring different properties of regulating sequences that modulate expression of catalytic biomolecules by recording that information into the DNA sequence of the same catalytic biomolecule using microfluidic techniques. | 2021-11-18 |
20210355487 | METHODS AND KITS FOR IDENTIFYING CANCER TREATMENT TARGETS - In one aspect, the present disclosure provides a method for identifying treatment targets relating to tumors. In another aspect, the present disclosure provides a method for identifying biomarkers and molecular features of normal and cancer cells. | 2021-11-18 |
20210355488 | Anti-CRISPR Nucleic Acid Inhibitors of CRISPR-Cas Effector Enzymes - A CRISPR inhibitor molecule is provided, comprising an artificial nucleic acid construct having a first polynucleotide, the inhibitor molecule capable of establishing several points of contact with a CRISPR protein and high binding affinity thereto, is provided. The first polynucleotide may comprise a sequence selected from the group consisting of: a polynucleotide that interacts with a protospacer adjacent motif (PAM)-interaction (PI) domain of a CRISPR-associated (Cas) protein, a polynucleotide that interacts with a guide sequence of a crRNA or an equivalent position of a single-guide RNA, and a polynucleotide that interacts with a repeat region of a tracrRNA or an equivalent position of a single-guide RNA. The CRISPR inhibitor molecule may also comprise a second polynucleotide and a linker. Methods of using the CRISPR inhibitor molecule in therapeutic agent selection and creation, as well as part of a therapeutic treatment, are also provided. | 2021-11-18 |
20210355489 | NOVEL TREATMENT FOR NEAT1 ASSOCIATED DISEASE - An isolated or purified antisense oligomer for modifying RNA cleavage and processing in the NEAT1 gene transcript or part thereof. | 2021-11-18 |
20210355490 | STING-DEPENDENT ACTIVATORS FOR TREATMENT OF DISEASE - The present disclosure relates, in general, to oligonucleotides that stimulate STING (STimulator of INterferon Genes) activity and increase activity of immune cells. The disclosed STING activators (STAVs) are useful in the treatment of cancer and other immune-mediated conditions. | 2021-11-18 |
20210355491 | OLIGONUCLEOTIDES FOR MSH3 MODULATION - This disclosure relates to novel MSH3 targeting sequences. Novel MSH3 targeting oligonucleotides for the treatment of neurodegenerative diseases are also provided. | 2021-11-18 |
20210355492 | CARGO LOADED EXTRACELLULAR VESICLES - The application relates to extracellular vesicles derived from red blood cells and particularly, although not exclusively, extracellular vesicles derived from red blood cells containing a cargo. The cargo may comprise small molecules, proteins, nucleic acids or components of the CRISPR/Cas9 gene editing system. The extracellular vesicles derived from red blood cells may be used in the treatment of medical disorders such as a genetic disorder, inflammatory disease, cancer, autoimmune disorder, cardiovascular disease or a gastrointestinal disease. Also provided is a method for loading the cargo into the extracellular vesicles derived from red blood cells by electroporation. | 2021-11-18 |
20210355493 | OLIGONUCLEOTIDE MEDIATED NO-GO DECAY - The present disclosure provides oligomeric compounds comprising a modified oligonucleotide that induces no-go decay of a target mRNA. In certain embodiments, the modified oligonucleotide is complementary to a region within the 3′ half of the coding region of the target mRNA. | 2021-11-18 |
20210355494 | METHODS AND COMPOSITIONS FOR EDITING RNAS - Provided are methods for editing RNA by introducing a deaminase-recruiting RNA in a host cell for deamination of an adenosine in a target RNA, and deaminase-recruiting RNAs used in the RNA editing methods and compositions comprising the same. | 2021-11-18 |
20210355495 | METHODS TO ELIMINATE CANCER STEM CELLS BY TARGETING CD47 - Described herein is the discovery that cancer stem cells (CSCs) can be induced to differentiate by altering CD47 signaling. Provided herein are methods and compositions for inducing differentiation of cancer stem cells, for instance irreversible differentiation, including methods of treating subjects with cancer such as breast cancer, colon cancer, lung cancer, ovarian cancer, or melanoma, and including metastatic as well as primary cancer. Also provided are methods for treating subjects with triple negative breast cancers involving forcing differentiation of bCSCs of the subjects through targeting of CD47. | 2021-11-18 |
20210355496 | COMPOSITIONS AND METHODS INVOLVING APTAMER SWITCH POLYNUCLEOTIDES - The disclosure provides aptamer switch polynucleotides whose kinetics and effective binding affinity to a target analyte can be independently tuned. The aptamer switch polynucleotides comprise an aptamer, an intramolecular linker, and a displacement strand. | 2021-11-18 |
20210355497 | COMPOUNDS AND METHODS FOR REDUCING FXI EXPRESSION - Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of FXI RNA in a cell or subject, and in certain instances reducing the amount of FXI protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to prevent, treat, or ameliorate at least one symptom of a thromboembolic condition without a significant increase in a bleeding risk. Such thromboembolic conditions include deep vein thrombosis, venous or arterial thrombosis, pulmonary embolism, myocardial infarction, stroke, thrombosis associated with chronic kidney disease or end-stage renal disease (ESRD), including thrombosis associated with dialysis, or other procoagulant condition. Such symptoms include decreased blood flow through an affected vessel, death of tissue, and death. | 2021-11-18 |
20210355498 | YEAST PROMOTERS FROM PICHIA PASTORIS - In accordance with the invention, isolated nucleic acids, expression methods, host cells, expression vectors, and DNA constructs for producing proteins, and proteins produced using the expression methods are described. More particularly, nucleic acids isolated from | 2021-11-18 |
20210355499 | Plant Vectors, Compositions and Uses Relating Thereto - The present disclosure relates to a single stranded RNA vector suitable for introducing a therapeutic agent, such as a peptide, a protein or a small RNA, into a host plant. The vector does not encode for any movement protein or coat protein, but is capable of capable of systemic and phloem-limited movement and replication within the host plant. | 2021-11-18 |
20210355501 | INTERLEUKIN-8 FOR MAINTENANCE OF HUMAN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME AND USES THEREOF - Methods are disclosed for enhancing growth of a human acute myeloid leukemia (AML) sample, a human myelodysplastic syndrome (MDS) sample, a human IL-8 dependent tumor sample, human preleukemia cells, and a human preleukemia clone or subclone ex vivo or in a xenograft animal model comprising adding human interleukin-8 (hIL-8) or a hIL-8 agonist to the sample or administering hIL-8 or a hIL-8 agonist to the animal model or expressing a gene encoding hIL-8 or a hIL-8 agonist in the animal model. The invention also provides a transgenic animal that expresses a gene encoding human interleukin-8 (hIL-8) or a hIL-8 agonist, which can be used to test the effectiveness of treatments for AML, MDS and IL-8 dependent tumors. | 2021-11-18 |
20210355502 | MATERIALS AND METHODS FOR THE CORRECTION OF RETINITIS PIGMENTOSA - Methods and compositions for modifying the coding sequence of endogenous genes using rare-cutting endonucleases. The methods and compositions described herein can be used to modify the endogenous USH2A gene. | 2021-11-18 |
20210355503 | COMPOSITIONS AND METHODS FOR MANUFACTURING GENE THERAPY VECTORS - Disclosed are methods for the production and/or purification of a recombinant AAV (rAAV) particle from a mammalian host cell culture. | 2021-11-18 |
20210355504 | AAV1 VECTORS AND USES THEREOF FOR TREATMENT OF OTIC INDICATIONS - The invention provides AAV1 vectors that can be used to transduce multiple inner ear cell types and their use for treatment of hearing loss, deafness, tinnitus, and vestibular dysfunction. | 2021-11-18 |
20210355505 | SYNP78 (PROA27), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN RETINAL GANGLION CELLS - The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 1800 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene. | 2021-11-18 |
20210355506 | COMPOSITIONS AND METHODS FOR TREATING GM1 GANGLIOSIDOSIS AND OTHER DISORDERS - The disclosure provides gene therapy vectors and methods of use thereof for treating genetic diseases, such as lysosomal storage diseases. For example, the disclosure provides gene therapy vectors and methods for treating GM1 gangliosidosis. The disclosure also provide methods for making the provided gene therapy vectors. | 2021-11-18 |
20210355507 | CLOSED-ENDED LINEAR DUPLEX DNA FOR NON-VIRAL GENE TRANSFER - Aspects of the disclosure relate to a nucleic acid comprising a heterologous nucleic acid insert flanked by interrupted self-complementary sequences, wherein one self-complementary sequence is interrupted by a cross-arm sequence forming two opposing, lengthwise-symmetric stem-loops, and wherein the other of the self-complementary sequences is interrupted by a truncated cross-arm sequence. Methods of delivering the nucleic acid to a cell are also provided. | 2021-11-18 |
20210355508 | Method for Modulating RNA Splicing by Inducing Base Mutation at Splice Site or Base Substitution in Polypyrimidine Region - Provided is a method for modulating RNA splicing by inducing a base mutation at a splice site or a base substitution in a polypyrimidine region. The method comprises expressing a targeting cytosine deaminase in a cell, to induce AG at a 3′ splice site of an intron of interest in a gene of interest to mutate into AA, or to induce GT at a 5′ splice site of the intron of interest in a gene of interest to mutate to AT, or to induce a plurality of Cs in a polypyrimidine region of the intron of interest in a gene of interest to respectively mutate into Ts. The method specifically blocks an exon recognition process, modulates a selective splicing process of endogenous mRNA, induces exon skipping, activates an alternative splice site, induces mutually exclusive exon conversion, induces intron retention, and enhances an exon. | 2021-11-18 |
20210355509 | ALTERNATIVE SPLICING REGULATION OF GENE EXPRESSION AND THERAPEUTIC METHODS - Provided herein are chimeric transactivator minigenes, where the alternative splicing of the minigene determines whether a transactivator is expressed. Expression of the transactivator results in the transcription of a target gene that is under the control of a designer promoter sequence. Alternatively, provided herein are chimeric target gene minigenes, wherein the alternative splicing of the minigene directly determines whether the target gene is expressed. The target gene may encode an inhibitory RNA, a CRISPR-Cas9 protein, or a therapeutic protein. | 2021-11-18 |
20210355510 | ENZYMATIC PROCESS FOR PRODUCTION OF MODIFIED HOP PRODUCTS - The present invention relates to a process for producing a beer tittering agent via enzyme catalyzed bioconversion of hop-derived isoalpha acids to dihydro-(rho)-isoalpha acids and to the novel enzyme catalysts which may be employed in such a process. | 2021-11-18 |
20210355511 | PROCESS FOR SIMULTANEOUS PRODUCTION OF CITRIC ACID AND CELLULOLYTIC ENZYMES - The present invention relates to a process for simultaneous production of citric acid and cellulolytic enzymes. The batch process comprising (i) adding slurry of a pre-treated lignocellulosic biomass or cellulose in a fermentation media; (ii) inoculating 10% (v/v) active liquid seed culture of | 2021-11-18 |
20210355512 | USE OF MARINE ALGAE FOR CO-PRODUCING ALKENONES, ALKENONE DERIVATIVES, AND CO-PRODUCTS - A method comprising a series of selective extraction techniques for the parallel production of biodiesel and isolation of several valuable co-products including an alkenone hydrocarbon mixture of the kerosene/jet fuel range (primarily C10-, C12-, and C17-hydrocarbons) and fucoxanthin, a high-valued carotenoid, from the marine alkenone-producing microalgae | 2021-11-18 |
20210355513 | Method for Preparing Phosphatidylserine by Ultrasonic-assisted Enzymatic Hydrolysis - An ultrasonic-assisted method for preparing phosphatidylserine, comprising the following steps: adding 100-130 parts of phospholipid into a mixture of 150-200 parts of L-serine, 10-20 parts of anhydrous calcium chloride and 400-500 parts of pure water, adding 20-25 parts of phospholipase D for enzymatic hydrolysis reaction, and applying ultrasound in the enzymatic hydrolysis reaction for treatment. The present invention uses an ultrasonic treatment technology to assist phospholipase D to act on phosphatidylcholine and serine to undergo an enzymatic hydrolysis reaction to prepare phosphatidylserine, and at the same time, the ultrasonic frequency, ultrasonic intensity, ultrasonic power, ultrasonic time, ultrasonic temperature, enzyme activity and other parameters are controlled synergistically, so that the enzymatic hydrolysis conversion rate is 98% or higher. | 2021-11-18 |
20210355514 | MODIFIED POLYPEPTIDE WITH ATTENUATED ACTIVITY OF CITRATE SYNTHASE AND METHOD FOR PRODUCING L-AMINO ACID USING THE SAME - The present disclosure relates to a modified polypeptide with attenuated activity of citrate synthase and a method for producing an aspartate-derived L-amino acid using the modified polypeptide. | 2021-11-18 |
20210355515 | METHOD FOR THE FERMENTATIVE PRODUCTION OF L-LYSINE USING AN L-LYSINE EXCRETING BACTERIUM OF THE SPECIES CORYNEBACTERIUM GLUTAMICUM HAVING A COMPLETELY OR PARTLY DELETED WHIB4 GENE - Fermentative production of L-lysine using an L-lysine excreting bacterium of the species | 2021-11-18 |
20210355516 | ENZYME-CATALYZED SYNTHESIS OF (1S,5R)-BICYCLOLACTONE - An enzyme-catalyzed synthesis of (1S,5R)-bicyclolactone. A first genetically-engineered bacterium containing Baeyer-Villiger monooxygenase gene and a second genetically-engineered bacterium containing glucose dehydrogenase gene are constructed and then suspended with culture medium to prepare a first suspension and a second suspension, respectively. The first and second suspensions are centrifuged to respectively produce a first supernatant containing Baeyer-Villiger monooxygenase and a second supernatant containing glucose dehydrogenase, which are mixed. The mixed supernatant is then mixed with a raceme of a substituted bicyclo[3.2.0]-hept-2-en-6-one, a solvent, a hydrogen donor and a cofactor to perform an asymmetric Baeyer-Villiger oxidation to produce the (1S,5R)-bicyclolactone, where an amino acid sequence of the Baeyer-Villiger monooxygenase is shown in SEQ ID NO:1. | 2021-11-18 |
20210355517 | METHOD FOR BIOSYNTHESISING DIOSMETIN AND/OR HESPERETIN IN A MICROORGANISM - The present invention relates to a recombinant microorganism which is modified to be capable of producing diosmetin and/or hesperetin and to the use thereof for producing diosmetin and/or hesperetin. | 2021-11-18 |
20210355518 | GENERATING NUCLEIC ACIDS WITH MODIFIED BASES USING RECOMBINANT TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE - Disclosed herein include methods of generating a single stranded deoxyribonucleic acid (ssDNA) scaffold comprising nucleotides with modified bases using a recombinant terminal deoxynucleotidyl transferase (TdT). The recombinant TdT can comprise an amino acid sequence that is at least 80% identical to a | 2021-11-18 |
20210355519 | DEMAND SYNTHESIS OF POLYNUCLEOTIDE SEQUENCES - The invention provides methods of synthesizing a product DNA molecule having a desired and/or defined sequence. The methods involve annealing at least one long oligonucleotide and at least one short oligonucleotide to at least one anchor strand having a sequence at least partially complementary to the at least one long and at least one short oligonucleotide. After annealing, at least one long oligonucleotide bound to an anchor strand abuts at least one short oligonucleotide bound to the same anchor strand. The anchor strand has one or more non-standard nucleotides, and optionally one or more degenerate nucleotides. The method involves ligating the abutting at least one long oligonucleotide and at least one short oligonucleotide to form a dsDNA molecule. The invention also provides methods of synthesizing DNA molecules by assembling oligonucleotide members of a library that contains less than 20,000 members that can be assembled into all possible DNA sequences. | 2021-11-18 |
20210355520 | METHOD FOR THE PRODUCTION OF AMINO SUGAR CONTAINING PRODUCTS - A method or producing amino sugar (containing) products using metabolically engineered microorganisms is disclosed, wherein the conversion of UDP-N-acetylglucosamine to cell envelope precursors and molecules is reduced by altering the activity of enzymes involved in the synthesis of cell envelope precursors and molecules. | 2021-11-18 |
20210355521 | KIT FOR DIAGNOSING INFECTION WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) BY DETECTING MAGNESIUM IONS - Provided is a diagnostic kit for determining infection with Methicillin-Resistant | 2021-11-18 |
20210355522 | INHIBITORS OF RNA-GUIDED NUCLEASE ACTIVITY AND USES THEREOF - Compositions and methods are provided for the inhibition of the function of RNA guided endonucleases, including the identification and use of such inhibitors. Methods of identifying inhibitor compounds of RNA guided nucleases, assays for detecting nuclease activity and compounds for use therein are also provided. | 2021-11-18 |
20210355523 | RT-qPCR Molecular Detection and Diagnosis - Provided herein are oligonucleotide probes for detecting 2019 novel coronavirus (2019-nCoV). The probes are modified at their 5′ ends with a fluorophore (e.g., fluorescein), and are also modified (e.g., at their 3′ ends) with a moiety capable of quenching fluorescence from the fluorophore. The moiety is based on the IQ-4 or IQ-2 quencher. Also provided are kits including one or more of such oligonucleotide probes, and methods of detecting 2019-nCoV and/or diagnosing COVID-19 using the oligonucleotide probes and kits described herein. | 2021-11-18 |
20210355524 | Methods for Nucleic Acid Sequencing - The present disclosure provides systems and methods for sequencing and analysis of nucleic acids. | 2021-11-18 |
20210355525 | Methods, Devices and Kits for Preparing Nucleic Acid Samples For Storage and Analysis - Methods, devices and kits for sampling, releasing and stabilizing nucleic acid, including RNA and DNA, from virus, bacteria yeast and other cells is described. The released and stabilized nucleic acid may be analyzed and quantified without further sample preparation at the point of care or may be transported to a testing laboratory by shipment and analyzed directly. The nucleic acid, which can be RNA, remains safe and stable so that shipping by normal means including government postal service may be used. In addition, the RNA sample remains stable so that analysis can be performed immediately after receipt of sample or after storage for days, weeks or months. Storage may be at room or ambient temperature or cooler temperatures. The sampling apparatus used to acquire samples can interface with nucleic detection and measurement instrumentation including high throughput, parallel processing instruments. | 2021-11-18 |
20210355526 | MOLECULAR TYPING OF MICROBES - A method for characterizing spacer regions in a CRISPR array from each of a plurality of microbial DNA isolates, the method comprising: in a separate reaction well for each of the plurality of microbial DNA isolates, performing a PCR with a microbial DNA isolate and at least one pair of primers configured to amplify spacers within a CRISPR array comprised in the microbial DNA isolate and to add at least one barcode that uniquely indexes the PCR products produced in the reaction well, pooling the PCR products produced from each of the plurality of microbial DNA isolates; and sequencing the pooled PCR products with a Next Generation Sequencing (NGS) system to obtain an aggregated sequence data. | 2021-11-18 |
20210355527 | METHODS FOR DETECTION OF MICROBIAL NUCLEIC ACIDS IN BODY FLUIDS - Methods for detecting microbial nucleic acids in a body fluid of a subject are provided. The methods include highly sensitive and specific procedures for detecting DNA derived from the bacteria such as | 2021-11-18 |
20210355528 | KITS FOR SINGLE-STEP ANALYTE DETECTION WITH PROCESS CONTROL - Kits for detecting analyte polynucleotides and an internal control in a sample. Included in the kit are an internal control polynucleotide and amplification reagents to co-amplify a first analyte polynucleotide and the internal control. Also included are first and second hybridization probes, each having a label indistinguishable from the other. The probes are respectively capable of hybridizing with a first analyte amplicon and an internal control amplicon. The first and second labels are indistinguishable homogeneous labels. | 2021-11-18 |
20210355529 | POLYPHENOLIC ADDITIVES IN SEQUENCING-BY-SYNTHESIS - The invention relates to methods, compositions, devices, systems and kits as described including, without limitation, reagents and mixtures for determining the identity of nucleic acids in nucleotide sequences using, for example, sequencing by synthesis methods. In particular, the present invention contemplates the use of polyphenolic compounds, known as antioxidant additives, to improve the efficiency of Sequencing-By-Synthesis reactions. For example, gallic acid (GA) is shown herein to be one of many exemplary SBS polyphenolic additives. | 2021-11-18 |
20210355530 | Oligonucleotide Paints - Novel methods for making high resolution oligonucleotide paints are provided. Novel, high resolution oligonucleotide paints are also provided. | 2021-11-18 |
20210355531 | COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE VARIANTS - In some aspects, the present disclosure provides methods for identifying sequence variants in a nucleic acid sample. In some embodiments, a method comprises identifying sequence differences between sequencing reads and a reference sequence, and calling a sequence difference that occurs in at least two different circular polynucleotides, such as two circular polynucleotides having different junctions, or two different sheared polynucleotides as the sequence variant. In some aspects, the present disclosure provides compositions and systems useful in the described method. | 2021-11-18 |
20210355532 | METHODS AND REAGENTS FOR DETECTING AND ASSESSING GENOTOXICITY - Methods, systems, and kits with reagents for assessing genotoxicity, are disclosed herein. Genotoxicity and their mechanisms of action can be determined within a few days of a subjects exposure. Some embodiments of the technology are directed to utilizing Duplex Sequencing for assessing a genotoxic potential of a compound (e.g., a chemical compound) in an exposed subject. Other embodiments of the technology are directed to utilizing Duplex Sequencing for determining a mutation signature associated with a genotoxic agent; and/or a safe threshold level of genotoxin exposure. Additional embodiments of the technology are directed to identifying one or more genotoxic agents a subject may have been exposed to by comparing the subjects DNA mutation spectrum to the mutation spectra of known mutagenic compounds. Once a genotoxin exposure in a subject is identified, or confirmed, then a prophylactic, and/or inhibitory therapeutic course of treatment is provided. | 2021-11-18 |
20210355533 | TCR/BCR Profiling - This present disclosure relates to systems, methods, and compositions useful for profiling T cell receptor (TCR) and B cell receptor (BCR) repertoire using next-generation sequencing (NGS) methods. The present disclosure also relates to systems and methods for diagnosing, treating, or predicting infection, disease, medical conditions, therapeutic outcome, or therapeutic efficacy based on the TCR/BCR profile data from a subject in need thereof. | 2021-11-18 |
20210355534 | COMPOSITIONS AND METHODS FOR POLYNUCLEOTIDE SEQUENCING - Methods and compositions for characterizing a target polynucleotide, including, characterizing the sequence of the target polynucleotide, using the fractional translocation steps of the target polynucleotide's translocation through a pore. | 2021-11-18 |
20210355535 | SYSTEMS AND METHODS FOR EPIGENETIC SEQUENCING - The present invention generally relates to microfluidics and/or epigenetic sequencing. In one set of embodiments, cells contained within a plurality of microfluidic droplets are lysed and the DNA (e.g., from nucleosomes) within the droplets are labeled, e.g., with adapters containing an identification sequence. The adapters may also contain other sequences, e.g., restriction sites, primer sites, etc., to assist with later analysis. After labeling with adapters, the DNA from the different cells may be combined and analyzed, e.g., to determine epigenetic information about the cells. For example, the DNA may be separated on the basis of certain modifications (e.g., methylation), and the DNA from the separated nucleosomes may be sequenced using techniques such as chromatin immunoprecipitation (“CUP”). In some cases, the DNA sequences may also be aligned with genomes, e.g., to determine which portions of the genome were epigenetically modified, e.g., via methylation. | 2021-11-18 |
20210355536 | METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLING - The present disclosure provides methods for determining the ploidy status of a chromosome in a gestating fetus from genotypic data measured from a mixed sample of DNA comprising DNA from both the mother of the fetus and from the fetus, and optionally from genotypic data from the mother and father. The ploidy state is determined by using a joint distribution model to create a plurality of expected allele distributions for different possible fetal ploidy states given the parental genotypic data, and comparing the expected allelic distributions to the pattern of measured allelic distributions measured in the mixed sample, and choosing the ploidy state whose expected allelic distribution pattern most closely matches the observed allelic distribution pattern. The mixed sample of DNA may be preferentially enriched at a plurality of polymorphic loci in a way that minimizes the allelic bias, for example using massively multiplexed targeted PCR. | 2021-11-18 |
20210355537 | COMPOSITIONS AND METHODS FOR IDENTIFICATION OF A DUPLICATE SEQUENCING READ - The present invention provides methods, compositions and kits for detecting duplicate sequencing reads. In some embodiments, the duplicate sequencing reads are removed. | 2021-11-18 |
20210355538 | USE OF MUCOSAL TRANSCRIPTOMES FOR ASSESSING SEVERITY OF ULCERATIVE COLITIS AND RESPONSIVENESS TO TREATMENT - The present disclosure provides methods for assessing responsiveness or non-responsiveness to a therapeutic agent (e.g., steroid therapy, anti-TNF therapy or anti-integrin α4β7 therapy) in ulcerative colitis (UC) subjects based on gene signatures. The methods may further comprise identifying suitable treatment for the patient based on the gene signatures. | 2021-11-18 |
20210355539 | BIOMARKERS FROM MINIMALLY INVASIVE SAMPLING REFLECTIVE OF THE PLACENTAL IMMUNE MICROENVIRONMENT - The present invention relates to minimally-invasive methods of measuring placenta-specific miRNA to assess immunotolerance during pregnancy. Disclosed are methods to diagnose and treat pathologic pregnancy based upon the altered level of placenta-specific miRNA in a pregnant mother. | 2021-11-18 |
20210355540 | ASSESSMENT OF RISK OF ANEUPLOIDY - The present disclosure relates generally to methods and materials for use in detecting abnormalities of the number of whole chromosomes or chromosome regions (aneuploidy). It has particular utility for assessing the risk of aneuploidy of eggs (i.e., oocytes), fertilised eggs or embryos developed therefrom in the context of in vitro fertilisation. | 2021-11-18 |